Complement Inhibition in ANCA-Associated Vasculitis
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.888816
Abstract: Efficacy of immunosuppressive treatment of Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is complicated by its toxicity. With the replacement of cyclophosphamide with rituximab, serious adverse events seem to be associated especially with high-dose corticosteroids. Activation… read more here.
Keywords: associated vasculitis; inhibition anca; anca associated; complement inhibition ... See more keywords